A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

This study is looking for adults aged 18 or older who have been diagnosed with advanced germ cell, endometrial, or ovarian cancer. This means your cancer has either come back or hasn't responded to previous treatments. For endometrial or ovarian cancer, your cancer cells must also have a specific marker that the new medicine targets. You should generally be well enough to take part in a study, meaning you can mostly look after yourself.

There are also some reasons why you might not be able to join. For example, if you've had major surgery very recently (within the last 28 days), or if you've had other cancers in the past three years (unless they were certain types of skin cancer or early-stage cervical or breast cancer that have been fully treated). People with serious infections or certain types of cancer spread to the brain or spinal cord would also not be able to participate. Your study doctor will check all these details carefully.

If you join this study, you will receive the study medicine, BI 3820768, through an injection. The injections will be given either once a week for six weeks, and then every three weeks after that. You might stay in the study for up to three years if the treatment is helping you. During this time, you will need to come to the study clinic regularly, and sometimes these visits might require you to stay overnight. Doctors will frequently check on your general health, take blood samples, and monitor the size of your tumours and whether the cancer has spread. They will also keep a close eye on any side effects you might experience. This helps them find the safest and most effective dose of the medicine.